Mosaic Immunoengineering Inc
Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on advancing and commercialization of immunotherapies for the treatment of cancer. It engages in pursuing new product candidates and platforms to build a new pipeline based on immunotherapies. Mosaic ImmunoEngineering, Inc. was founded in 2020 and is based in Huntington Beach, California.
Mosaic Immunoengineering Inc (CPMV) - Total Liabilities
Latest total liabilities as of September 2025: $7.36 Million USD
Based on the latest financial reports, Mosaic Immunoengineering Inc (CPMV) has total liabilities worth $7.36 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Mosaic Immunoengineering Inc - Total Liabilities Trend (2016–2024)
This chart illustrates how Mosaic Immunoengineering Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Mosaic Immunoengineering Inc Competitors by Total Liabilities
The table below lists competitors of Mosaic Immunoengineering Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Imperial Pacific Ltd
AU:IPC
|
Australia | AU$1.81 Million |
|
Reliant Holdings Inc
OTCQB:RELT
|
USA | $4.21 Million |
|
FendX Technologies Inc.
PINK:FDXTF
|
USA | $1.25 Million |
|
BUZZI UNICEM
BE:UCM
|
Germany | €2.14 Billion |
|
Libental
TA:LBTL
|
Israel | ILA103.35 Million |
|
Lingo Media Corporation
PINK:LMDCF
|
USA | $591.24K |
Liability Composition Analysis (2016–2024)
This chart breaks down Mosaic Immunoengineering Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 133.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mosaic Immunoengineering Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mosaic Immunoengineering Inc (2016–2024)
The table below shows the annual total liabilities of Mosaic Immunoengineering Inc from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $6.93 Million | +14.53% |
| 2023-12-31 | $6.05 Million | +17.58% |
| 2022-12-31 | $5.15 Million | +67.70% |
| 2021-12-31 | $3.07 Million | +248.56% |
| 2020-12-31 | $880.34K | +382.13% |
| 2019-12-31 | $182.59K | -19.99% |
| 2018-12-31 | $228.21K | +168.99% |
| 2017-12-31 | $84.84K | +49.93% |
| 2016-12-31 | $56.59K | -- |